News & Updates

A multicentre, randomized, phase III trial conducted by researchers from the Chinese University of Hong Kong (CUHK) demonstrated a significant reduction in 1-year recurrence of non–muscle-invasive bladder cancer (NMIBC) with the use of en bloc vs standard resection (SR).

After 5 years of follow-up, median progression-free survival (PFS) has still not been reached in patients with advanced non-small-cell lung cancer (NSCLC) treated with lorlatinib in the phase III CROWN study, corresponding to the longest PFS ever reported with any single-agent molecular targeted treatment in advanced NSCLC and across all metastatic solid tumours.

A recent study has found more potential drug‒drug interactions in breast cancer patients receiving doxorubicin and cyclophosphamide regimen in the Drugs.com database than in the Lexicomp and Micromedex databases.

The addition of statins to standard adjuvant breast cancer treatment, particularly in combination with chemotherapy, appears to improve patient survival, suggests a study presented at ESMO Breast Cancer 2024.

Long-term data from the phase III PANTHER trial demonstrate improved breast cancer recurrence-free survival (BCRFS) with tailored dose-dense adjuvant chemotherapy as opposed to standard adjuvant chemo in individuals with high-risk early breast cancer.

In previously treated patients with EGFR-mutated advanced non-small-cell lung cancer (NSCLC), subcutaneous (SC) amivantamab combined with lazertinib shows noninferior pharmacokinetic and efficacy profiles compared with the approved intravenous (IV) formulation of amivantamab, according to the phase III PALOMA-3 trial.

HER2-positive metastatic breast cancer (mBC) patients who had been treated with trastuzumab emtansine continue to enjoy survival benefits with trastuzumab deruxtecan (TD) relative to those who received treatment of physician’s choice (TPC), as shown by the updated results of the DESTINY-Breast (DB)-02 study. TD also boasts of a manageable safety profile, with no long-term toxicity.

Consolidation treatment with the PD-L1 antibody durvalumab following concurrent chemoradiotherapy significantly prolonged overall (OS) and progression-free survival (PFS) in patients with limited-stage small-cell lung cancer (SCLC), as shown in the interim analysis of the phase III ADRIATIC trial.